UK-based Glide Pharma has signed an agreement with medical device manufacturer Nypro Healthcare to complete design optimisation of its needle-free delivery system Glide SDI (solid dose injector).
With this delivery system, drugs and vaccines can be injected in a solid dosage form without the requirement of a needle.
Using a spring mechanism, the one-click, pen-sized and reusable Glide SDI system administers a tiny solid dosage below the patient’s skin, where it dissolves and releases the medicine.
The collaboration between the two firms will ensure the design of the device and its components are optimised for production scale-up, as well as address the requirements of patients, including self-administration.
Glide Pharma CEO Dr Mark Carnegie-Brown noted that this agreement marks a milestone for its Glide SDI device, as it will enable the firm to complete the final phase of development prior to production scale up.
"As a recognised leader in the development and manufacturing of precision devices we believe that Nypro Healthcare is the perfect partner to work with Glide Pharma on advancing our novel delivery system," added Carnegie-Brown.
Nypro Healthcare business development vice president Chris Nother said the Glide SDI is an innovative delivery system, which is very different from other technologies currently on the market.
"Nypro Healthcare is delighted to have been selected as Glide Pharma’s partner to help progress the development of this exciting new technology," added Nother.
Apart from eliminating the need for refrigeration, Glide SDI offers potential to modify the release of medicines and boost stability.
The medicines are supplied in pre-filled disposable cassettes.
Solid dose formulations remove the risk of needle-stick injuries and eliminate the time-consuming process of reconstitution.
During clinical investigations, the Glide SDI was preferred over traditional needles and syringes.